GSK plc
GSK.LHealthcareLSEDrug Manufacturers - General · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, GSK plc focuses on Drug Manufacturers - General services and products. GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United. The $73.01B market capitalization puts GSK.L squarely in large-cap range for its industry. It operates through Commercial Operations and Total R&D segments.
Market Cap
$73.01B
Beta
0.30
P/E (TTM)
12.82
P/E (Fwd)
9.34
EPS (TTM)
$1.42
EPS (Fwd)
$1.95
ROE
40.9%
ROA
10.0%
Cash
$3.44B
Total Debt
$19.11B
Free CF
$3.02B
52W Change
23.3%
Annual Financials
Cash vs Debt
GSK plc carries $19.11B in total debt against $3.44B in cash reserves — debt is roughly 5.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $3.02B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 40.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.0% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $29.32B to $32.67B.
GSK.L's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GSK plc's trajectory.